Sector News

UCB sells generics unit Kremers Urban for $1.53 billion

November 7, 2014
Life sciences
UCB is selling its US specialty generics business Kremers Urban Pharmaceuticals to two private equity groups for almost $1.53 billion.
 
The cash from Advent International and Avista Capital Partners will be used by Belgium-headquartered UCB “to reduce indebtedness and increase the company’s capacity strategic investments”. The deal is expected to close by the first quarter of 2015.
 
Kremers Urban focuses on difficult, ‘high-barrier-to-entry’ generics and UCB got hold of the New Jersey-based business through its acquisition of Schwarz Pharma in 2006.
 
UCB chief financial officer Detlef Thielgen said it “has been an important enabler” to build the group’s operations. However, “it’s now the right time from a value perspective to focus on our core business” of neurology and immunology.
 
The sale was announced after another Belgian firm, the over-the-counter group Omega Pharma, announced it was being acquired by Perrigo in a deal worth $4.5 billion.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.